Healthcare entity
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention ANKTIVA, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline. The 7 average consequence score is above the beat benchmark of 6.6 in the same window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention ANKTIVA, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.3 across the same-window beat baseline. The 7 average consequence score is above the beat benchmark of 6.6 in the same window. ImmunityBio Inc. appears in 1 tracked Healthcare story from March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ImmunityBio Inc.. Shared-story counts are live from our verified record — not editorial picks.
Expected Regional Launch
Anticipated availability of ANKTIVA in Macau oncology centers.
Macau SAR Approval
Macau Health Bureau grants regulatory clearance for ANKTIVA.
U.S. Commercial Launch
ImmunityBio begins commercial distribution of ANKTIVA in the U.S.
U.S. FDA Approval
ANKTIVA receives first-ever approval for NMIBC in the United States.
ImmunityBio Inc. has received regulatory approval for its flagship immunotherapy, ANKTIVA, in the Macau Special Administrative Region of China. This milestone marks the first international expansion for the IL-15 superagonist following its 2024 U.S. FDA approval, positioning the company to tap into the significant oncology market in the Greater Bay Area.
Source: finance.yahoo.com · insidermonkey.com
ImmunityBio Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
